Lori is a seasoned veteran in the healthcare space beginning her career as a CCRN working in critical care, trauma and emergency medicine at Yale New Haven Hospital, Emory University Hospital and St Joseph’s of Atlanta. She transitioned into the medical device industry as a Clinical Specialist with Datascope, now Maquet and with a track record of success took on increasing levels of leadership completing her 10 year tenure as the Vice President of North American Sales. She spent time as a regional Corporate Sales Director for Medtronic and then moved over to Covidien Endo mechanical where she spent 4 years as the VP of Sales and Marketing. Most recently she served as the VP of the US for Cordis, a Johnson and Johnson company. Lori is known as a champion of change management and passionate about delivering growth. She has led numerous women’s leadership imperatives and currently serves as the VP on the Atlanta Chapter board for the Healthcare Business women’s Association. Lori earned a BSN from Southern Connecticut State University.
Chief Operation Officer and General Manager Israel
Gal leads R&D, manufacturing and worldwide logistic activities of the company. Gal is an industry veteran with more than 18 years of experience in leading product development and engineering teams at early stage medical device companies and international public corporations. Prior to Dune, he was head of R&D at Lumenis Corp. where he managed a team of over 45 engineers. Prior to that, he was head of R&D at SHL Telemedicine, developing medical applications that are conveniently used from home. He earned a BSc degree in mechanical engineering from Ben-Gurion University in Israel
Chief Financial Officer
Lior leads all global financial activities at Dune. He has more than 11 years of experience in establishing effective Finance and Accounting operations in a variety of settings including technology and industrial companies. Prior to Dune, he held 8 years of senior financial positions, most recently as VP Finance, at Cyren (formerly Commtouch), an Israeli-based TASE and NASDAQ dual listed company. In Cyren he led a team of 12 employees in 5 worldwide locations in various areas of financial management. During the three years prior to that time, he served as a Deputy Controller at Delta Galil Industries Ltd. Also, Lior spent 3 years in public accounting, at KPMG in Israel. Lior is a Certified Public Accountant (Israel), and holds a B.A. in business administration majoring in accounting and an M.B.A. majoring in Finance, both from the College of Management Academic Studies.
Chief Science Officer
Gil leads of all the scientific related activities at Dune, including Regulatory and Clinical and IP. He has more than 15 years of experience in R&D, as well as leadership roles, in various fields, including Medical devices, Bio-tech, and Clean-tech. Gil has a PhD in Physics, from the Hebrew University in Jerusalem.
Iddo leads Dune’s research and product development activities. He has over 10 years of experience in R&D leading Dune’s core technology group, including early stage R&D, product development and engineering. Iddo earned a BSc in Physics and Computer Science at the Hebrew University in Jerusalem, and a PhD at Princeton University, NJ, USA.
Board of Directors
Amos is a Special Partner at Apax Partners managing the existing Apax healthcare venture portfolio and a private active investor. Amos joined Apax in 1997 and until 2007 was an Equity Partner and the Head of Apax Healthcare Europe and co-Head of Apax’s global healthcare practice. Amos led the Apax investments in Dune as Chairman since 2004. Amos directed many of Apax’s investments in medtech and biotechnology in Europe, the US and Israel among these Aerovance, Astex, Cadent, Compugen. Prior to Apax, Amos was an executive involved in turnarounds of manufacturing companies in Israel and CEO of a speciality pharma company in the US which he founded and sold. Amos received his MBA from Harvard Business School, MSc from the Weizmann Institute and BSc from the Hebrew University.
Dr. Paul Enever
Paul is an adviser with Canepa U.S., where he oversees the Canepa Advanced Healthcare Fund’s strategy and investments of its Advanced Healthcare portfolio. He serves on the Boards of Directors of Cardiva Medical, Dune Medical, and Knome. Before joining Canepa, Paul was a partner with McKinsey and Company. Previously, Paul worked within the R&D organization at Sandoz Pharmaceuticals and MIT’s Biotechnology Process Engineering Center. He has a B.S. in chemical engineering from Rensselaer Polytechnic Institute and a Ph.D. in chemical engineering from the University of Minnesota where he studied wound healing and tissue engineering. For his work, Paul was the recipient of both a National Science Foundation Graduate Fellowship and the Whitaker Foundation Graduate Fellowship in Biomedical Engineering.
Gary is Chairman, Chief Investment Officer and Co-founder of Orchard Global Capital Group. Prior to this role, Gary was founder and Chief Executive of Newshore Capital Group and Chief Executive and Chief Investment Officer of ChapelGate Asset Management. Gary ranks as one of the world’s most successful global credit hedge fund managers, leveraging and building on his career as a derivatives trader, portfolio manager and structurer at institutions such as Deutsche Bank and the Ontario Financing Authority. He received his BA (Hons) in Economics from Queen’s University and earned his MS in Information Management from Syracuse University.
Dr. Dan Hashimshony
Founder & Executive Board Advisor
Dan is a veteran medical device executive and entrepreneur. Prior to founding Dune he was the Chief Scientist of X-Technologies (acquired by Guidant Corp in 2003) where he led the development of a miniature X-ray emitting devices for Brachytherapy. Prior to that, he work in the semiconductors industry (Sela- Semiconductor Engineering Laboratories Ltd), focusing on the creation of novel devices for remote sensing relying on terahertz technology. As one of the pioneers of THZ radiation devices Dan was engaged in various development and academic projects in the field. Dan received his PhD in physics from the Racah Institute of Physics at Hebrew University Of Jerusalem.
Daniel J. Levangie
Daniel Levangie, an experienced executive with senior operating experience in the field of medical devices and in vitro diagnostics, is co-founder and Managing Partner of newly formed ATON Partners, a private investment and management consulting firm. Most recently Mr. Levangie was Chief Executive Officer of Dune Medical Devices and co-founder and Managing Partner of Constitution Medical Investors, Inc. (CMI) a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in July 2013.
Prior to the above, Mr. Levangie held a variety of executive management positions with Cytyc Corporation until the acquisition of Cytyc Corporation by Hologic, Inc. in October of 2007. Mr. Levangie held a variety of senior management positions with Cytyc Corporation including Executive Vice President and Chief Operating Officer, Chief Executive Officer and President of Cytyc Health Corporation, Executive Vice President and Chief Commercial Officer and President, Cytyc Surgical Products Division from July 2006 until October, 2007.
Prior to joining Cytyc Corporation in 1992, Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories, North Chicago, IL.
Mr. Levangie resides in Boston, MA with his wife Joan, and is a member of the Board of Directors of Exact Sciences, Inc., Liposcience, Inc., Insulet Corporation, and Dune Medical Devices. Mr. Levangie, a graduate of Northeastern University in Boston, is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School.